-
Risk Reduction, Clinical Trials Are Focus of Atlanta Community EventCancer researchers, patient advocates and community members gathered for a public forum presented by the American Association for Cancer Research.
by Kevin McLaughlin
-
Making Clinical Trials More InclusiveBroadening clinical trial eligibility criteria to include cancer patients who also have other health conditions could increase trial enrollment.
by Ashley P. Taylor
-
What Do Clinical Trial Endpoints Really Measure?A study investigates whether a commonly used clinical trial endpoint, progression-free survival, can be used to predict quality of life.
by Jon Kelvey
-
2018: This Year in Cancer NewsThe Cancer Today editorial staff selects some of the most interesting and impactful reporting, research and perspectives of 2018.
by Cancer Today Staff
-
2018 SABCS: Choosing the Right TreatmentStudies presented at the 2018 San Antonio Breast Cancer Symposium investigate when patients with early-stage breast cancer or precancerous breast conditions benefit from receiving less intense treatment.
by Kate Yandell
-
The Roots of Rural Health DisparitiesNew research shows that rural cancer patients have the same health outcomes as urban cancer patients so long as they are involved in a clinical trial.
by Cheryl Platzman Weinstock
-
Will Right to Try Increase Access to Experimental Treatments?The recently passed Right to Try Act is meant to provide patients with greater access to experimental therapies. Patient advocates are divided on whether the law will benefit patients.
by Marci A. Landsmann
-
Omitting ObesityMany cancer clinical trials do not track what proportion of enrolled patients are obese, a study finds. These patients may be underrepresented in research.
by Cici Zhang
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
Multiple myeloma survivor Jonathan Gluck reflects on uncertainty, and the scientific progress that has kept him living with cancer for more than two decades.
by Eric Fitzsimmons
The Enduring Importance of Cancer Disparities ResearchOpening session from AACR conference highlights how perseverance and adversity have informed cancer disparities research over the years.
by Eric Fitzsimmons
Most Cancer Survivors Don’t Meet Healthy Diet GoalsDespite research linking fruits and vegetables to cancer survival, many people do not change their eating habits after diagnosis.
by Darlene Dobkowski
Many People Don’t Get Colonoscopy After Receiving Abnormal Blood TestsAbout half of people who receive abnormal results from colorectal cancer screening tests don’t follow up with a colonoscopy.
by Laura Gesualdi Gilmore
-
Keeping Hope Alive—Why the Schlueters Rally for Medical ResearchRichard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed his treatment.
-
Cancer in the Rearview Mirror: 15 Years of AACR Cancer Progress Report Survivor StoriesCancer survivors profiled over the past 15 years in the AACR Cancer Progress Reports shared updates on their lives and the progress made against cancer.
Cancer Research at a Crossroads
